PHR1199
氨基葡萄糖
Pharmaceutical Secondary Standard; Certified Reference Material
别名:
D- (+)-氨基葡萄糖 盐酸盐, GLH, 2-氨基-2-脱氧-D-葡萄糖 盐酸盐, 壳糖胺 盐酸盐
产品名称
氨基葡萄糖, Pharmaceutical Secondary Standard; Certified Reference Material
InChI
1S/C6H13NO5.ClH/c7-3-5(10)4(9)2(1-8)12-6(3)11;/h2-6,8-11H,1,7H2;1H/t2-,3-,4-,5-,6?;/m1./s1
SMILES string
Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
InChI key
QKPLRMLTKYXDST-NSEZLWDYSA-N
grade
certified reference material
pharmaceutical secondary standard
agency
traceable to Ph. Eur. Y0001406
traceable to USP 1294207
API family
glucosamine
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
mp
190-194 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-30°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Analysis Note
These secondary standards offer multi-traceability to the USP and EP (PhEur) primary standards, where they are available.
Application
氨基葡萄糖盐酸盐可用作药物参考标准品，用于通过高效液相色谱（HPLC）测定药物制剂和血浆样品中的分析物。
这些二级标准品是合格的认证标准物质（CRM）。它们适用于多种分析应用，包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。
Biochem/physiol Actions
葡萄糖胺是一种氨基糖，是己糖胺生物合成途径的前体，可导致形成UDP-N-乙酰葡糖胺(UDP-GlcNAc)，然后将其用于制备糖胺聚糖、蛋白多糖和糖脂。 D-（+）-葡萄糖胺抑制念珠菌酵母菌株与细菌菌株唾液链球菌的共聚集。
General description
用于质量控制的制药二级标准品，为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。
氨基葡萄糖盐酸盐是一种用于治疗小动物退行性关节疾病的处方药。
氨基葡萄糖盐酸盐是一种用于治疗小动物退行性关节疾病的处方药。
Other Notes
要查看该材料的分析证书示例，请在下面的栏位中输入LRAB3705。这只是一个示例证书，可能不是您收到的批次。
该认证参考物质（CRM）根据ISO 17034 和 ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在分析证书上找到。
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Development, comparison, and peak validation of a high-performance liquid chromatography method for direct determination of glucosamine hydrochloride in pharmaceutical formulations
Jin P, et al.
Journal of Liquid Chromatography and Related Technologies, 34(20), 2533-2547 (2011)
Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC
Liang Z, et al.
Journal of Pharmaceutical and Biomedical Analysis, 20(5), 807-814 (1999)
Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects
Muniyappa R, et al.
Diabetes, 55(11), 3142-3150 (2006)
Oshra Betzer et al.
ACS nano, 8(9), 9274-9285 (2014-08-19)
A critical problem in the development and implementation of stem cell-based therapy is the lack of reliable, noninvasive means to image and trace the cells post-transplantation and evaluate their biodistribution, final fate, and functionality. In this study, we developed a
Ji-Sun Hwang et al.
Metabolism: clinical and experimental, 64(3), 368-379 (2014-12-18)
This study investigated the potential of glucosamine (GlcN) to affect body weight gain and insulin sensitivity in mice normal and at risk for developing diabetes. Male C57BL/6J mice were fed either chow diet (CD) or a high fat diet (HFD)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持